We think Hims & Hers's Q3 2026 growth moved revenue, not profit. The market reads 49% revenue growth and a second straight quarter of acceleration as the business recovering. By our arithmetic, each subscriber brings in about $105 a month now against $85 in early 2025, but Hims keeps about $60 of gross profit from them, no more than it did then. The new dollars come from branded GLP-1 drugs that Novo Nordisk prices, and soon Eli Lilly too, so in weight loss Hims earns a distributor's cut, and its growth rate overstates what the platform is gaining.
| Period | Monthly revenue per subscriber | Monthly gross profit per subscriber |
|---|---|---|
| Q1 2025 | $85 | $62 |
| Q2 2025 | $76 | $58 |
| Q3 2025 | $81 | $60 |
| Q4 2025 | $83 | $60 |
| Q1 2026 | $80 | $52 |
| Q2 2026 | $92 | $59 |
| Q3 2026 | $105 | $60 |
The evidence
Where the extra revenue went
Until early 2026, Hims's weight-loss business ran on compounded semaglutide made in its own pharmacies, a product it priced itself. Two deals replaced it with branded drugs priced by the companies that make them.
- Novo Nordisk, March 9, 2026
- Drugs on Hims
- Wegovy pills and injections, Ozempic
- Price to the patient
- Not disclosed
- Eli Lilly, November 6, 2026
- Drugs on Hims
- Zepbound injection, Foundayo pill
- Price to the patient
- Same cash price as anywhere: from $299 a month (Zepbound), $149 (Foundayo)
| Deal | Drugs on Hims | Price to the patient |
|---|---|---|
| Novo Nordisk, March 9, 2026 | Wegovy pills and injections, Ozempic | Not disclosed |
| Eli Lilly, November 6, 2026 | Zepbound injection, Foundayo pill | Same cash price as anywhere: from $299 a month (Zepbound), $149 (Foundayo) |
With Novo, Hims also agreed to stop advertising compounded GLP-1s and keep them only "on a limited scale", and Novo dismissed its patent lawsuit, without prejudice, so it could refile. With Lilly, Hims committed never to offer compounded copies of Lilly's drugs. The price column matters most for the moat. A patient pays Hims what they'd pay anywhere else, and the drugmaker sets that price. Hims can win the visit, the prescription and the delivery, but the product margin sits with the drugmaker. Lilly's drugs aren't in the chart yet; the deal was signed after the quarter closed.
- Revenue
- Q3 2025
- $599M
- Q2 2026
- $753M
- Q3 2026
- $890M
- Rest of world revenue
- Q3 2025
- $55M
- Q2 2026
- $131M
- Q3 2026
- $233M
- Of which Eucalyptus
- Q3 2025
- None (bought June 2026)
- Q2 2026
- Part quarter, not given
- Q3 2026
- About $135M (per the CFO)
- Subscribers, end of quarter
- Q3 2025
- 2.47M
- Q2 2026
- 2.89M
- Q3 2026
- 2.79M
- Gross margin
- Q3 2025
- 74%
- Q2 2026
- 64%
- Q3 2026
- 57%
- Marketing spend
- Q3 2025
- $232M
- Q2 2026
- $262M
- Q3 2026
- $247M
| Measure | Q3 2025 | Q2 2026 | Q3 2026 |
|---|---|---|---|
| Revenue | $599M | $753M | $890M |
| Rest of world revenue | $55M | $131M | $233M |
| Of which Eucalyptus | None (bought June 2026) | Part quarter, not given | About $135M (per the CFO) |
| Subscribers, end of quarter | 2.47M | 2.89M | 2.79M |
| Gross margin | 74% | 64% | 57% |
| Marketing spend | $232M | $262M | $247M |
Subscribers fell by about 100,000 from June. CFO Yemi Okupe gave two reasons on the earnings call: "measured marketing spend in our domestic weight loss specialty" and "brand migrations in our international markets". Marketing was down only about 6% from Q2. A US weight-loss customer who can get the same branded drug at the same price elsewhere has to be won with ads each time, and that is what a 6% trim exposed. Some of the drop is also patients on cheap compounded semaglutide leaving as Hims phased it out, which points the same way: the product they stayed for is gone.
Counter-case
The case against us: it's Eucalyptus, and it's already turning
The strongest objection is that our chart blends two businesses. Eucalyptus, consolidated for its first full quarter, sells branded GLP-1s at low margins in Australia, the UK, Germany, Canada and Japan, and Okupe said on the call that it contributed about $135 million of the $233 million in rest-of-world revenue. He said "the scaling of branded weight loss products in our international business, which carry lower gross margins" drove most of the margin drop from Q2. US revenue grew 21%. Hims doesn't report gross margin by region, so the US business could still be earning more per subscriber than a year ago.
The chart itself also shows a recovery. Gross profit per subscriber rose about 15% from the Q1 2026 low, and marketing fell from 39% of revenue to 28% over the year, so gross profit after marketing per subscriber is a little higher than a year ago. CEO Andrew Dudum's case is that "in healthcare, whoever owns the customer relationship wins," backed by "more than 1 million square feet of pharmacy, lab, and compounding infrastructure." Okupe expects "gross margin declines to start to moderate as the pace of mix shifts towards international and weight loss specialty begins to moderate."
Our answer is that the recovery so far only returns Hims to its 2025 level while revenue per subscriber is a quarter higher, and that the US offers no separate evidence it is doing better. If the platform's pull is real, gross profit per subscriber should climb past its old range once Eucalyptus laps its first year in mid-2027. We've set the bar at $66 a month by August 2027; if Hims clears it, we're wrong.
Positioning
What it means for the stock
The framework still rates Hims's subscription bundle as a moat, and it doesn't score weight loss on its own; narrowing in that category is our reading. Weight loss, Hims's biggest growth driver, is now a resale business at the drugmaker's price, and the pricing power in it sits with Eli Lilly and Novo Nordisk. Our Lilly Q3 piece argued Lilly could absorb its own GLP-1 price cuts; this quarter shows where a distributor lands. For a holder, that means valuing Hims on gross profit per subscriber, not revenue. The scorecard below sets the framework's live scores for all three side by side.
Resells branded GLP-1s at the makers' prices; Q3 2026 gross margin 57%
Sets the self-pay price of Zepbound and Foundayo on Hims
Brought Wegovy and Ozempic to Hims in March 2026
| Name | ||||
|---|---|---|---|---|
| HIMSHims & Hers Health | 54 | 73 | 88 | 71 |
| LLYEli Lilly | 71 | 81 | 66 | 73 |
| NVONovo Nordisk | 54 | 49 | 85 | 59 |
Next read
Eli Lilly Q3 2026: The GLP-1 Price Cut Its Margin Absorbed
Lilly's realized GLP-1 prices fell 15% in Q3 2026, and the worry is that the price war has started eating its moat. If unit costs had stayed flat, that cut would have pulled its gross margin down to about 81%. It printed 84.4%. We read that gap as manufacturing scale being spent, and it's the number to watch.
Keep readingWhat would prove this wrong
HoldingWe're wrong if Hims & Hers's gross profit per subscriber (quarterly gross profit divided by average subscribers, divided by three; about $60 in Q3 2026) reaches $66 or more in any quarter reported by August 2027, or if gross margin returns above 65% while monthly revenue per subscriber stays above $100.
Sources
- [1]Hims & Hers Health, Inc. reports third quarter 2026 financial results (Form 8-K) — Hims & Hers Health, Inc., November 9, 2026 · Filing
- [2]Hims & Hers Health, Inc. reports second quarter 2026 financial results (Form 8-K) — Hims & Hers Health, Inc., August 10, 2026 · Filing
- [3]Hims & Hers Health, Inc. reports first quarter 2026 financial results (Form 8-K) — Hims & Hers Health, Inc., May 11, 2026 · Filing
- [4]Hims & Hers Health, Inc. reports fourth quarter and full year 2025 financial results — Hims & Hers Health, Inc., February 23, 2026 · Press release
- [5]Hims & Hers Q3 2026 earnings call transcript — Investing.com, November 10, 2026 · Transcript
- [6]Lilly and Hims & Hers expand access to FDA-approved Lilly medicines — Eli Lilly and Company, November 6, 2026 · Press release
- [7]Hims & Hers announces strategic shift for US weight loss business — Hims & Hers Health, Inc., March 9, 2026 · Press release
More research
Intuitive Surgical Stock Before Q3 2026 Earnings: Boston Scientific Shows How Rivals Take Share, and Where to Look
Intuitive reports on October 20 with Medtronic's Hugo and J&J's Ottava both cleared in the US, and we think Boston Scientific's lost PFA share shows the rivals' clearance date matters less than how often a customer can try them.
October 19, 2026ReadModerna Stock Before ESMO 2026: The Data Can Prove a Melanoma Drug, the Price Assumes a Platform
Moderna had more than tripled from its pre-readout close by October 16, and its October 24 ESMO data can show how good a melanoma drug intismeran is, but we think the price is paying for an mRNA cancer platform that only a randomized win in a second tumor type can prove.
October 18, 2026Read